



JC11 Rec'd PCT/PTO SEP 27 2001

Attorney Docket No. 56001 (46342)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Mori, et al.

U.S.S.N.: 09/869540 Art Unit:

FILED: December 27, 1999 Examiner: Unknown

FOR: SCREENING METHOD

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on September 25, 2001.

By: Norah C. Sullivan
Norah C. Sullivan

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Date: September 25, 2001

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. **LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION**

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. **COPIES**

- a. ☒ Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.

III. CONCISE EXPLANATION OF THE RELEVANCE
(check at least one box)

a. ☒ Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).

b. ☒ A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:

For reference CH See English Translation enclosed herein

c. ☐ The following additional information is provided for the Examiner's consideration:

FEES

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b)
(check one box)

a. ☒ within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.

b. ☐ within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.

c. ☐ before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below, or, if no certification has been made, charge our deposit

account a fee in the amount of \$240.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):
(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).

- a. ☐ No certification; therefore, a fee in the amount of _____ is required by 37 C.F.R. § 1.17(p).
or
b. ☐ See the certification below. No fee is required.

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby certifies that

- a. ☐ each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS;
or
b. ☐ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.
c. ☐ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

☐ Please charge Deposit Account No. 04-1105 in the amount of _____ for the above-indicated fee. A triplicate copy of this paper is attached.




No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition, if necessary) and charge the appropriate fee to Deposit Account No. 04-1105.


Respectfully submitted,

Date: September 25, 2001



John B. Alexander (Reg. No. 48,399)
DIKE, BRONSTEIN, ROBERTS & CUSHMAN
Intellectual Property Practice Group
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209

Tel: (617) 439-4444

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT 	ATTY DOCKET NO.	SERIAL NO.
	56001	09/869,540
	APPLICANT(S) Mori, M.	
	FILING DATE 12/27/99	GROUP NO.

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
BA	EP-A-848060	12/1/1997	—			
BB	WO 99/28492	12/2/1998				
BC	WO 96/18651	12/15/1995	—			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

✓ CA	Shimonura, Y. et al., <i>B.B.R.C.</i> , Vol. 261 (3), 622-626, 1999
✓ CB	Kolakowski, L.F., et al., <i>FEBS Letters</i> , Vol. 398, 253-258, 1996
✓ CC	Nahon, J.L., et al., <i>Endocrinology</i> , Vol. 125 (4), 2056-2065, 1989
✓ CD	Vaughan, J.M., et al., <i>Endocrinology</i> , Vol. 125 (3), 1660-1665, 1989
✓ CE	Thompson, Robert C., et al., <i>DNA and Cell Biology</i> , Vol. 9 (9) 637-645, 1990
✓ CF	Breton, C., et al., <i>Mol. Brain Res.</i> , Vol. 18 (4), 297-310, 1993
✓ CG	Lakaye, B., et al., <i>Biochemica et Biophysica Acta</i> , Vol. 1401 (2), 216-220, 1998
✓ CH	Tkhashi, K., et al., <i>Kagaku to Seibutsu</i> , Vol. 34, No. 7, 444-450, 1996 and translation thereof
✓ CI	Shimada, M., et al., <i>Nature</i> , Vol. 396, 670-674, 1998
✓ CJ	Bächner, D., et al., <i>FEBS Letters</i> , 00 (1999), 1-3
✓ CK	Drozdz, R., et al., <i>Journal of Peptide Science</i> , Vol. 1, 58-65, 1995
✓ CL	Chambers, J., et al., <i>Nature</i> , Vol 400, 261-265, 1999
✓ CM	Saito, Y., et al., <i>Nature</i> , Vol. 400, 265-269, 1999
CN	Lembo, P.M.C., et al., <i>Nature Cell Biology</i> , Vol. 1, 267-271, 1999

EXAMINER:

DATE: